`Patent No. 9,220,698
`Paper No. 9
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`DR. REDDY’S LABORATORIES, INC.,
`Petitioner
`
`v.
`
`POZEN INC. and HORIZON PHARMA USA, INC.,
`Patent Owners
`
`_____________________
`
`Inter Partes Review IPR2018-00894
`Patent No. 9,220,698 B2
`_____________________
`
`PETITIONER’S REPLY TO PATENT OWNERS’ OPPOSITION TO
`MOTION FOR JOINDER WITH IPR2017-01995
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pursuant to 35 U.S.C. § 315(c) and 37 C.F.R. § 42.23 Petitioner Dr. Reddy’s
`
`Laboratories, Inc. (“DRL” or “Petitioner”) submits this Reply to Patent Owners
`
`Pozen, Inc.’s and Horizon Pharma USA Inc.’s (“Patent Owners”) Opposition to
`
`Petitioner’s Motion for Joinder with pending IPR2017-01995 (the “Mylan IPR”)
`
`regarding U.S. Patent No. 9,220,698 (the ’698 patent”) (Paper 8). Mylan
`
`Pharmaceuticals Inc. (“Mylan”) is the Petitioner in IPR2017-01995.
`
`On April 30, 2018 Petitioner informed the Board and all parties to IPR2018-
`
`00894 and IPR2017-01995 by email that:
`
`Mylan has agreed to share its experts with DRL and that Mylan
`
`consents to joinder of IPR2018-00894 with instituted IPR2017-01995
`
`(where Mylan is the Petitioner). As already set forth in DRL’s Motion
`
`for Joinder in IPR2018-00894, DRL agrees to take a “backseat”
`
`position to Mylan if the Motion for Joinder is granted, and to let Mylan
`
`take the lead.
`
`DRL’s Joinder Motion had already set forth that DRL would not rely on the
`
`declarations of its own experts if Mylan agreed to share its experts with DRL.
`
`In order to simplify the proceeding further, Petitioner will rely on the
`
`same experts as Mylan, should Mylan permit Petitioner to do so. If
`
`Mylan allows Petitioner to retain the same experts, Petitioner will
`
`withdraw its expert declarations of Drs. Solny and Bergstrom and rely
`
`
`
`1
`
`
`
`
`
`solely on the declarations and testimony of Mylan’s experts, Drs. Metz
`
`and Mayersohn.
`
`Joinder Motion (Paper 3, at 7) (emphasis added). Though Patent Owners assert that
`
`“DRL has made no representation that it would withdraw its own expert declarations
`
`or otherwise agree to not rely on the direct testimony of its own experts in any way,”
`
`(Paper 8, at 3), DRL’s statement block quoted immediately above is exactly that.
`
`Nevertheless, DRL reiterates that based on Mylan’s agreement to share its experts
`
`(Drs. Metz and Mayersohn) with DRL, DRL withdraws the declarations of its own
`
`experts (Drs. Solny and Bergstrom) and will not rely on them.
`
`Patent Owners raise further questions that Petitioner has already answered.
`
`DRL has already agreed to the “conditions” set forth set forth in the Conclusion of
`
`Patent Owners’ Opposition. See Joinder Motion, Paper 3, at 6-7, n.2-3.
`
`
`
`Contrary to Patent Owners’ assertion, Petitioner’s Joinder Motion and Petition
`
`are timely1 under 37 C.F.R. §§ 42.22 and 42.122(b) because Petitioner submitted
`
`
`1 Indeed, it is Patent Owners’ Opposition that is tardy. Patent Owners filed and
`
`served their Opposition to Petitioner’s Joinder Motion on May 9, 2018 – thirty-three
`
`(33) days after the April 6, 2018 filing and service of Petitioner’s Joinder Motion.
`
`This is not within the requisite one month time period set forth in 37 C.F.R. §
`
`42.25(a)(1).
`
`
`
`2
`
`
`
`
`
`both within one month of the March 8, 2018 date of institution of the Mylan IPR.
`
`Notwithstanding their assertion to the contrary in n.1 of their Opposition, Patent
`
`Owners may not refight the timeliness of the Mylan IPR here.
`
`For all the foregoing reasons, Petitioner respectfully requests that the Board
`
`institute IPR2018-00894 on the same grounds as in the Mylan IPR, and that this
`
`proceeding be joined with the Mylan IPR.
`
`Date: May 11, 2018
`
`
`
`Respectfully submitted,
`
`/ Alan H. Pollack /
`Alan H. Pollack (Reg. No. 39,802)
`Stuart D. Sender (Reg. No. 34,248)
`Louis H. Weinstein (Reg. No. 45,205)
`BUDD LARNER, P.C.
`150 John F. Kennedy Parkway
`Short Hills, NJ 07078
`apollack@buddlarner.com
`ssender@buddlarner.com
`lweinstein@buddlarner.com
`Telephone: (973) 379-4800
`Facsimile: (973) 379-7734
`
`
`
`3
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105, I certify that on this eleventh day
`
`of May, 2018, the foregoing REPLY TO PATENT OWNERS’ OPPOSITION
`
`TO MOTION FOR JOINDER WITH IPR2017-01995 was served via electronic
`
`mail to Lead and Backup Counsel in this IPR and Lead and Backup Counsel for
`
`Petitioner in IPR2017-01995 at the following E-mail addresses:
`
`BMWhite@perkinscoie.com
`ANero@perkinscoie.com
`RSwanson@perkinscoie.com
`BBeel@perkinscoie.com
`stephen.hash@bakerbotts.com
`escordino@cooley.com
`tblinka@cooley.com
`jgraves@cooley.com
`msampson@bakerbotts.com
`jgritton@bakerbotts.com
`
`
`Dated:
`
`
`
`
`
`
`
`
`
`
`
`
`May 11, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` By: /s/ Alan H. Pollack
`
` Alan H. Pollack
`
` Reg. No. 39,802
`
`
`
`
`
`
`
`4
`
`